Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug

Molecular Cancer Therapeutics

Volumn 1, Issue 11, 2002, Pages 901-911

  De Groot, Franciscus M H ^a,f   Broxterman, Henk J ^b   Adams, Hans P H M ^a   Van Vliet, Alexandra ^c   Tesser, Godefridus I ^a   Elderkamp, Yvonne W ^b   Schraa, Astrid J ^d   Kok, Robbert Jan ^e   Molema, Grietje ^c,d   Pinedo, Herbert M ^b   Scheeren, Hans W ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Ansynth Service BV   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f Syntarga BV Toernooiveld   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZYL ALCOHOL; 4-AMINOBENZYL ALCOHOL; ALPHAVBETA5 INTEGRIN; ANTINEOPLASTIC AGENT; ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; BENZYL ALCOHOL DERIVATIVE; DOXORUBICIN; INTEGRIN; LIGAND; OLIGOPEPTIDE; PEPTIDE; PLASMIN; PRODRUG; VITRONECTIN RECEPTOR;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CANCER INVASION; CELL ADHESION; CHEMICAL MODEL; CHEMISTRY; CYTOLOGY; DOSE RESPONSE; DRUG DESIGN; ENDOTHELIUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IC 50; METABOLISM; METASTASIS; MOLECULAR GENETICS; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE; SYNTHESIS; VASCULAR ENDOTHELIUM;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BENZYL ALCOHOLS; BINDING SITES; CELL ADHESION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG DESIGN; ENDOTHELIUM; ENDOTHELIUM, VASCULAR; HUMANS; INHIBITORY CONCENTRATION 50; INTEGRIN ALPHAVBETA3; INTEGRINS; LIGANDS; MODELS, CHEMICAL; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OLIGOPEPTIDES; PEPTIDES; PLASMIN; PRODRUGS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, VITRONECTIN;

EID: 0036725452     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Dubowchik, G. M., and Walker, M. A. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther., 83: 67-123, 1999. (Pubitemid 29438597)
2. de Groot, F. M. H., Damen, E. W. P., and Scheeren, H. W. Anticancer prodrugs for application in monotherapy: targeting hypoxia, tumor-associated enzymes, and receptors. Curr. Med. Chem., 8: 1093-1122, 2001. (Pubitemid 32633661)
3. Damen, E. W. P., de Groot, F. M. H., and Scheeren, H. W. Novel anthracycline prodrugs. Exp. Opin. Ther. Patents, 11: 651-666, 2001. (Pubitemid 32280070)
4. 3 for angiogenesis. Science (Wash. DC), 264: 569-571, 1994.
5. Mizejewski, G. J. Role of integrins in cancer: survey of expression patterns. Proc. Soc. Exp. Biol. Med., 222: 124-138, 1999.
6. Huang, X., Molema, G., King, S., Watkins, L., Edgington, G. S., and Thorpe, P. E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science (Wash. DC), 275: 547-549, 1997.
7. Koivunen, E., Wang, B., and Ruoslahti, E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology, 13: 265-270, 1995.
8. Assa-Munt, N., Jia, X., Laakkonen, P., and Ruoslahti, E. Solution structures and integrin binding activities of an RGD peptide with two isomers. Biochemistry, 40: 2373-2378, 2001. (Pubitemid 32171709)
9. Arap, W., Pasqualini, R., and Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (Wash. DC), 279: 377-380, 1998. (Pubitemid 28063372)
10. Ellerby, H. M., Arap, W., Ellerby, L. M., Kain, R., Andrusiak, R., Del Rio, G., Krajewski, S., Lombardo, C. R., Rao, R., Ruoslahti, E., Bredesen, D. E., and Pasqualini, R. Anticancer activity of targeted pro-apoptotic peptides. Nat. Med., 5: 1032-1038, 1999. (Pubitemid 29439574)
11. Khan, S. R., and Denmeade, S. R. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate, 45: 80-83, 2000.
12. Defeo-Jones, D., Garsky, V. M., Wong, B. K., Feng, D-M., Bolyar, T., Haskell, K., Kiefer, D. M., Leander, K., McAvoy, E., Lumma, P., Wai, J., Senderak, E. T., Motzel, S. L., Keenan, K., Van Zwieten, M., Lin, J. H., Freidinger, R., Huff, J., Oliff, A., and Jones, R. E. A peptide-doxorubicin prodrug activated by prostate specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat. Med., 6: 1248-1252, 2000.
13. Dubowchik, G. M., Mosure, K., Knipe, J. O., and Firestone, R. A. Cathepsin B-sensitive dipeptide prodrugs. Part 2: Models of anticancer drugs paclitaxel (Taxol®), mitomycin C and doxorubicin. Bioorg. Med. Chem. Lett., 8: 3347-3352, 1998. (Pubitemid 28547070)
14. Trouet, A., Passioukov, A., Van derpoorten, K., Fernandez, A-M., Abarca-Quinones, J., Baurain, R., Lobl, T. J., Oliyai, C., Shochat, D., and Dubois, V. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies. Cancer Res., 61: 2843-2846, 2001. (Pubitemid 32691922)
15. Yamashita, Y-I., and Ogawa, M. Cell biologic factors and cancer spread. Int. J. Oncol., 10: 807-813, 1997.
16. Schmitt, M., Wilhelm, O. G., Reuning, U., Krüger, A., Harbeck, N., Lengyel, E., Graeff, H., Gänsbacher, B., Kessler, H., Bürgle, M., Stürzebecher, J., Sperl, S., and Magdolen, V. The urokinase plasminogen activator system as a novel target for tumor therapy. Fibrinolysis Proteolysis, 14: 114-132, 2000. (Pubitemid 30409285)
17. Curran, S., and Murray, G. I. Matrix metalloproteinases, molecular aspects of their roles in tumor invasion and metastasis. Eur. J. Cancer, 36: 1621-1630, 2000. (Pubitemid 30616366)
18. de Groot, F. M. H., de Bart, A. C. W., Verheijen, J. H., and Scheeren, H. W. Synthesis and biological evaluation of novel prodrugs of anthracyclines for selective activation by the tumor-associated protease plasmin. J. Med. Chem., 42: 5277-5283, 1999. (Pubitemid 30020279)
19. de Groot, F. M. H., van Berkom, L. W. A., and Scheeren, H. W. Synthesis and biological evaluation of 2[prime]-carbamate-linked and 2[prime]-carbonate- linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin. J. Med. Chem., 43: 3093-3102, 2000. (Pubitemid 30626766)
20. Chakravarty, P. K., Carl, P. L., Weber, M. J., and Katzenellenbogen, J. A. Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin. J. Med. Chem., 26: 638-644, 1983.
21. de Groot, F. M. H., Loos, W. J., Koekkoek, R., van Berkom, L. W. A., Busscher, G. F., Seelen, A. E., Albrecht, C., de Bruijn, P., and Scheeren, H. W. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. J. Org. Chem., 66: 8815-8830, 2001. (Pubitemid 34042246)
22. 3- vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J. Biol. Chem., 276: 26340-26348, 2001.
23. van der Pluijm, G., Sijmons, B., Vloedgraven, H., van der Bent, C., Drijfhout, J-W., Verheijen, J., Quax, P., Karperien, M., Papapoulos, S., and Löwik, C. Urokinase-receptor-integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am. J. Pathol., 159: 971-982, 2001. (Pubitemid 32847188)
24. Simon, D. I., Wei, Y., Zhang, L., Rao, N. K., Xu, H., Chen, Z., Liu, Q., Rosenberg, S., and Chapman, H. A. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J. Biol. Chem., 275: 10228-10234, 2000. (Pubitemid 30202079)
25. Kaiser, E., Colescott, R. L., Bossinger, C. D., and Cook, P. I. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. Anal. Biochem., 34: 595-598, 1970.
26. Barton, G. M., Evans, R. S., and Gardner, J. A. F. Paper chromatography of phenolic substances. Nature (Lond.), 170: 249-250, 1952.
27. van Hinsbergh, V. W. M., and Draijer, R. In vitro models and functional studies of endothelium. Culture, characterization and application of human endothelial cells. In: A. J. Shaw (ed.), Cell Culture of Epithelial Tissues. A Practical Approach, pp. 87. New York: Oxford University Press, 1996.
28. Verheul, H. M. W., Jorna, A. S., Hoekman, K., Broxterman, H. J., Gebbink, M. F. B. G., and Pinedo, H. M. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood, 96: 4216-4221, 2000.
29. 3 in the disruption of the tumor vasculature induced by TNF and IFN-g. Nat. Med., 4: 408-414, 1998.
30. van Hensbergen, Y., Broxterman, H. J., Elderkamp, Y. W., Lankelma, J., Beers, J. J. C., Heijn, M., Boven, E., Hoekman, K., and Pinedo, H. M. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem. Pharmacol., 63: 897-908, 2002. (Pubitemid 34243003)
31. 3 integrin directed therapeutics. Bioconjug. Chem., 13: 128-135, 2002.
32. Carl, P. L., Chakravarty, P. K., and Katzenellenbogen, J. A. A novel connector linkage applicable in prodrug design. J. Med. Chem., 24: 479-480, 1981. (Pubitemid 11021878)
33. 15)-gastrin I and unsulfated cholecystokinin octapeptide. Int. J. Pept. Protein Res., 38: 555-561, 1991.
34. Kamber, B., Hartmann, A., Eisler, K., Riniker, B., Rink, H., Sieber, P., and Rittel, W. The synthesis of cysteine peptides by iodine oxidation of S-trityl-cysteine and S-acetamidomethyl-cysteine peptides. Helv. Chim. Acta, 63: 899-915, 1980.
35. Sieber, P., Kamber, B., Hartmann, A., Jöhl, A., Riniker, B., and Rittel, W. Totalsynthese von human insulin. IV. Beschreibung der endstufen. Helv. Chim. Acta, 60: 27-37, 1977. (Pubitemid 8017863)
36. Honzl, J., and Rudinger, J. Amino acids and peptides. XXXIII. Nitrosyl chloride and butyl nitrite as reagents in peptide synthesis by the azide method, suppression of amide formation. Collect. Czech. Chem. Commun., 91: 2391-2392, 1961.
37. Carl, P. L. Development of Target-oriented Anticancer Drugs, pp. 143-155. New York: Raven Press, 1983.